Form 10-Q MEDIFAST INC For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Medifast (MED) stock plunges on earnings miss, weak outlook
April 30, 2024 9:08 AM EDTMedifast (NYSE: MED), a wellness company known for its OPTAVIA brand, reported a significant decline in first-quarter revenue and earnings after the close on Monday, missing Wall Street estimates and projecting weaker-than-expected guidance for the second quarter. The company's shares plummeted 25% as investors reacted to the disappointing results and outlook.
For the first quarter ended March 31, 2024, Medifast's revenue fell to $174.7 million, a sharp 49.9% decrease from $349.0 million in the same quarter last year. This decline significantly missed the analyst consensus of $205.79 million. The company's adjusted earnings per share (EPS) for the quarter was $0.66,... More
Medifast (MED) PT Lowered to $25 at DA Davidson
April 30, 2024 5:00 AM EDTDA Davidson analyst Linda Bolton Weiser lowered the price target on Medifast (NYSE: MED) to $25.00 (from $40.00) while maintaining a Neutral rating.
The analyst comments "NEUTRAL-rated MED reported a small 1Q24 sales beat but profit missed consensus by 11% due to higher SG&A... More
